REFRACTORY THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: targeted drug takes aim at HRAS gene
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this mix can shrink or control th…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tested whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has spread or come back. It included 34 adults whose cancer had a specific gene change (RAS mutation) or no changes in RAS or RAF genes. The goa…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo shows promise for hard-to-treat thyroid cancer
Disease control OngoingThis study tests whether a two-drug targeted therapy (encorafenib and binimetinib) works better with or without the immunotherapy drug nivolumab for people with a specific type of advanced thyroid cancer (BRAF V600 mutant) that has spread and no longer responds to standard radioa…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated May 13, 2026 16:01 UTC